4 MENORAT HAMAOR ST., TEL AVIV, L3
InspireMD, Inc. Receives Nasdaq Delisting Notice for Non-Compliance
Director Resignation - Raymond W. Cohen Steps Down from Board
Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures
InspireMD, Inc. Increases Authorized Shares to 250 Million
Director Retirement - Paul Stuka Steps Down from InspireMD Board
Reports First Quarter 2026 Financial Results
Announces FDA Approval of Investigational Device Exemption for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System
InspireMD, Inc. Enters $75 Million Equity Distribution Agreement with BTIG
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Amended Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence